Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
Direct-Acting Antivirals Linked to Improved Outcomes in Chronic Hepatitis C All-cause mortality rate significantly lower in treated versus untreated group Dec 13, 2022
Abstinence Tied to Lower Mortality in Alcoholic Cirrhosis With Portal Hypertension Benefit observed even in patients with high-risk portal hypertension Dec 08, 2022
Liver-Related Death in Lean NAFLD; Gravity Causing IBS? Appendicitis and UC Risk News and commentary from the world of gastroenterology and hepatology Dec 01, 2022
Robotic Surgery Proves Its Mettle for Liver Cancer Fewer cases of liver failure, similar survival versus open liver resection in matched analysis Nov 23, 2022
IBD and Preterm Birth Risk; Leprosy Bacteria Promote Liver Growth; COVID and IBD News and commentary from the world of gastroenterology and hepatology Nov 17, 2022
Will Fresh Look at Obeticholic Acid Data in NASH Sway FDA? Latest REGENERATE analysis comes on heels of REVERSE flop Nov 11, 2022
Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitis Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH Nov 11, 2022
Novel Hepatitis B Drug Hints at Long-Term 'Functional Cure' for Some in Early Trial With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon Nov 10, 2022
Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH Nov 10, 2022
Maralixibat Takes Out the Itch of Rare Liver Disease Ileal bile acid transporter inhibitor could become second drug for PFIC Nov 09, 2022
Odevixibat Shows 'Encouraging Results' for Kids With Alagille Syndrome Significant improvements in itching, bile acid levels for rare, life-threatening liver disorder Nov 09, 2022
Acamprosate Appears Safe for People With AUD and Liver Disease Phase II data suggest drug is well-tolerated and can reduce cravings in this group of patients Nov 09, 2022
BP Control Beneficial for Liver Transplant Recipients Patients who kept their blood pressure under 140/90 mm Hg had better kidney function at 1 year Nov 07, 2022
Earlier Terlipressin May Be Better for HRS-AKI in Acute-on-Chronic Liver Failure More acute kidney injury reversals at 7 days and lower mortality with initiation at 12 hours Nov 07, 2022
Pandemic's Impact on Liver Disease in the Spotlight at Liver Meeting A roundup of news from the AASLD annual meeting Nov 04, 2022
FDA Rejects Hep D Drug; Cash for Colonoscopies; Mortality in MAFLD Without Obesity News and commentary from the world of gastroenterology and hepatology Nov 03, 2022
One in Eight U.S. Adult Deaths Involved Too Much Booze Study details premature deaths after excessive alcohol use pre-pandemic, especially in the young Nov 01, 2022
Entyvio for Kid IBD; Phase III Win in PFIC; Drug Flops for Eosinophilic Esophagitis News and commentary from the world of gastroenterology and hepatology Oct 27, 2022
New HRS Drug Cuts Need for Renal Replacement Tx After Liver Transplant Follow-up data from CONFIRM trial show terlipressin benefit in key subgroup Oct 25, 2022
New Standard-of-Care Therapy for Advanced Liver Cancer Stereotactic body radiotherapy plus sorafenib improves survival versus targeted drug alone Oct 24, 2022
FDA Approves New CTLA-4 Inhibitor for Cancer Treatment Tremelimumab (Imjudo), in combination with durvalumab, lands approval in advanced liver cancer Oct 24, 2022
Long-Term Xeljanz for UC; AGA Drops Obesity Drug Guidelines; PPIs & Cystic Fibrosis? News and commentary from the world of gastroenterology and hepatology Oct 20, 2022
Bariatric Surgery in NAFLD Tied to Lower Heart Disease Risk In a large cohort, surgery associated with 49% lower risk of CVD versus nonsurgical care Oct 07, 2022
Can Norovirus Trigger Crohn's? Phase III NASH Trial Flops; Social Isolation in IBD News and commentary from the world of gastroenterology and hepatology Oct 06, 2022
TETA4 Noninferior to Penicillamine for Stable Wilson's Disease Phase III study results led to trientine tetrahydrochloride's FDA approval for this rare disorder Oct 03, 2022
FDA Clears AI Polyp Detection Device; IBD and Sexual Issues; Stelara in Pregnancy News and commentary from the world of gastroenterology and hepatology Sep 29, 2022
Noninvasive Gastric Mapping; Best Foods for the Gut? Lab Score for Crohn's News and commentary from the world of gastroenterology and hepatology Sep 22, 2022
Obeticholic Acid Tied to Better Outcomes in Primary Biliary Cholangitis Study comparing randomized trial with two external cohorts showed fewer deaths, transplants Sep 22, 2022
FDA Finally OKs First Drug for Hepatorenal Syndrome Pivotal trial data showed terlipressin nearly doubled reversal of the condition Sep 15, 2022
Ryan Reynolds' Colonoscopy; NASH Drug Passes Phase II Test; New Drug Target in IBD? News and commentary from the world of gastroenterology and hepatology Sep 14, 2022
Predicting Crohn's Relapse; Sex After Hernia Repair; Bacteria and Anti-TNF Response News and commentary from the world of gastroenterology and hepatology Sep 01, 2022
FDA OKs First Treatment for Acid Sphingomyelinase Deficiency Enzyme replacement therapy reduces sphingomyelin accumulation Aug 31, 2022
IBD Biologics After COVID; Cutting Endoscopy Waste; New Humira Biosimilar OK'd News and commentary from the world of gastroenterology and hepatology Aug 25, 2022
'Alarming' Spike in Liver Disease Deaths; Can PPIs Cause Lupus? IBS and Depression News and commentary from the world of gastroenterology and hepatology Aug 18, 2022
Gut Bacteria Post-COVID; UC Remission Prediction; UC Flares with Stress News and commentary from the world of gastroenterology and hepatology Aug 11, 2022
CDC: Few Insured Patients With Hepatitis C Get Timely Treatment Not even one-third received curative drugs within a year of diagnosis Aug 10, 2022
More GI Docs, Fewer Alcoholic Liver Disease Deaths Study suggests access might account for 40% of alcohol-associated liver disease deaths nationally Aug 08, 2022
Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone Aug 04, 2022
Snoring & Liver Disease; Remicade's COVID Woes; Delays in Liver Cancer Treatment News and commentary from the world of gastroenterology and hepatology Aug 04, 2022
